Table 2.
Summary of Non-responders
| Patient | Age | Race/Gender | Smoking status | Histology | HER2 alteration | Testing Method | Other alterations | Systemic therapies*# | Best Responseˆ | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| #5 | 57 | A/M | Never | Adeno | A775_G776 insYVMA + amplification | Foundation One NGS | TERT promoter, TP53 C135F, NFKB1A amplification, NKX2-1 amplification | Carbo/pem, then pem maintenance X 6 mo | PR | |
| Afatinib X1.5 months | PD | |||||||||
| Nivolumab X 2 mo | PD | |||||||||
| Tras/Docetaxel X3 mo | Mixed response systemically, development of leptomeningeal disease | |||||||||
|
| ||||||||||
| #6 | 79 | A/M | <10 pack year | Adeno | A775_G776 insYVMA | Foundation One NGS | Carbo/pem, then pem maintenance X 3.5 mo | Tolerated therapy poorly, SD | ||
| Docetaxel/ramucirumab X 1 mo | Tolerated therapy poorly, SD | |||||||||
| Afatinib X1 month | Symptomatic progression | |||||||||
|
| ||||||||||
| #7 | 61 | A/F | Never | Adeno | L755A | STAMP NGS | TP53 c892G>T (E298X), RB1 c2101A>T (D701V) | Carbo/pem X2 mo | SD | |
| Paclitaxel X 3mo (therapy interrupted by WBRT) | SD | |||||||||
| Afatinib X1.5 months | PD | |||||||||
| Nivolumab (with 2 cycles of paclitaxel in between) X2 mo | PD | |||||||||
| Paclitaxel (re-challenge 2 month after last dose) X 1mo | PD | |||||||||
|
| ||||||||||
| #8 | 65 | A/M | <10 pack year | Adeno | V777delinsVG SP | Geneseeq Technology Inc NGS | JAK1 exon7 p.V310I (c.G928A) mutation, MED12 exon24 p.R1138G (c.C3412G) mutation, MET exon2 p.S204Y (c.C611A) mutation, TP53 p.P72R (c.C215G) mutation | Carbo/pem X 2 mo | PD | |
| Cis/Docetaxel X3 mo | SD | |||||||||
| Erlotinib X 4 mo | PD | |||||||||
| Gemcitabine X 2 mo | PD | |||||||||
| Afatinib X 2 mo | PD | |||||||||
|
| ||||||||||
| #9 | 43 | A/F | Never | Adeno | V776delinsVC | Geneseeq Technology Inc NGS | BLM p.S144X (c.C431A) mutation, BRCA1 exon4 p.S59X (c.C176A) mutation | Cis/pem, then cis/pem/bev X 4.5mo | Initial PD after cis/pem, then SD after addition of bev | |
| Tras/Paclitaxel X2 mo | PD | |||||||||
| Erlotinib X 1 month | PD | |||||||||
*
HER2 targeted therapies in bold
#
number indicates number of cycles unless otherwise specified
ˆ
as determined by RECIST v1.1 criteria
A: Asian
M: male
F: female
Adeno: adenocarcinoma
NGS: next generation sequencing
STAMP: Stanford solid tumor actionable mutation panel
SD: stable disease
WBRT: whole brain radiotherapy
Tras: trastuzumab
Bev: bevacizumab
Carbo: carboplatin
Cis: cisplatin
Pem: pemetrexed